Labcorp announces partnership with Roche to implement fully automated mass spectrometry
Labcorp becomes the first U.S. commercial lab to adopt Roche’s fully automated cobas Mass Spec Solution, streamlining clinical diagnostics and reducing turnaround times for patients and providers.
Labcorp announced that it is the first U.S. commercial laboratory with an agreement to implement Roche’s cobas Mass Spec Solution. This collaboration introduces fully automated mass spectrometry into routine clinical practice—accelerating turnaround times, improving accuracy, and expanding access to advanced diagnostics for patients and providers nationwide.
Historically, mass spectrometry required specialized expertise and manual processes, limiting its use in routine clinical labs. Roche’s cobas Mass Spec Solution changes that by automating the entire workflow—from sample preparation to result interpretation.
The cobas Mass Spec Solution will first be deployed at Labcorp’s Burlington, North Carolina laboratory, with launch expected in the first quarter of 2026, followed by expansion to additional Labcorp locations.
